EXEL vs IDXX
Exelixis vs Idexx Laboratories — AI-powered side-by-side comparison
VS
IDXX
Idexx Laboratories
69
Buy
| Metric | EXEL | IDXX |
|---|
| AI Score |
67
|
69
|
| Price |
$54.10
|
$586.77
|
| P/E Ratio |
16.43×
|
41.20×
|
| ROE |
36.2%
|
66.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
62.4%
|
| Debt / Equity |
0.09×
|
0.60×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
45.7
|
65.3
|
| Beta |
0.424
|
1.549
|
| Expected Upside |
+6.4%
|
+12.3%
|
AI Committee View
Current Innellis committee reasoning for EXEL versus IDXX.
IDXX leads by 2 points.
IDXX scores 69/100 (Buy) versus EXEL at 67/100 (Buy).
EXEL Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- MACD histogram negative -- bearish momentum — Technical
IDXX Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Stochastic RSI (90.3) confirms overbought conditions.
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.